000			nab a22 7a 4500
999			_c17654 _d17654
003			PC17654
005			20230803122847.0
008			230803b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa, eng
100			_91206 _aAyala Díaz, Rosa María _eHematología y Hemoterapia
245	0	0	_aLeucemia mieloide crónica en España: sus características de presentación han cambiado. Sección española del registro poblacional EUTOS. _h[artículo]
260			_bRevista clínica española, _c2016
300			_a216(6):293-300.
500			_aFormato Vancouver: Osorio S, Casado LF, Giraldo P, Maestro B, Andrade M, Redondo S et al. Leucemia mieloide crónica en España: sus características de presentación han cambiado. Sección española del registro poblacional EUTOS. Rev Clin Esp (Barc). 2016 Aug-Sep;216(6):293-300.
501			_aPMID: 27061504
504			_aContiene 23 referencias
520			_aObjectives: To provide more reliable data on the epidemiology of chronic myeloid leukaemia (CML) in Spain than are currently available. Material and methods: The EUTOS population-based project of European LeukemiaNet is a population registry of new CML cases in patients 18 years of age or older from 22 European areas. The Spanish section included the autonomous communities of Madrid, Castilla-La Mancha and Aragon, from 1-2-2010 to 31-12-2012. Results: A total of 250 cases were recorded in 35 months. The overall incidence was 1.08 cases/10(5) inhabitants-year, with a predominance of men (58%) and clear differences among the communities. The incidence standardised by age was similar (overall, 1.04; men, 1.31; women, 0.81). The median age was 54 years. The incidence increased with age, reaching a peak at>65 years, although 31.7% of cases appeared between the ages of 20 and 44 years. Four percent of cases were diagnosed in advanced stages (2.4% in accelerated phase, 1.6% in blast crisis), 56% were asymptomatic, 38% had splenomegaly, and the Sokal score was high in 11% (lower than what was previously reflected in the literature). Conclusions: The current incidence of CML in Spain is higher than previously reported and similar to that of the European studies. Unlike the classical descriptions, CML presented mostly in asymptomatic form, with no splenomegaly, less leucocytosis and in stages with better prognosis.
710			_9297 _aServicio de Hematología y Hemoterapia
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17654.pdf _ySolicitar documento
942			_2ddc _cART _n0